The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | Highlights from day 2: MRD in myeloma
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, shares some highlights from the second day of COMy 2022, which focused on the role of measurable residual disease (MRD) in multiple myeloma. Prof. Mohty discusses some of the sessions and debates held throughout the day, which addressed the role of MRD from a prognostic point of view, as well as its role in guiding treatment. Prof. Mohty also mentions some of the trials discussed during these sessions, including the MASTER-2 trial (NCT05231629) and the MIDAS (NCT04934475) trial, and concludes by addressing the value of MRD in real-life practice. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
